Developer docs
API playgroundTry for free, no card

Search company profiles

ProciseDx

Full company profile

uuid0002wkh

Namestring
ProciseDx
Legal namestring
ProciseDx Corporation
Websiteurl
procisedx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

ProciseDx is a point-of-care diagnostic platform company specializing in rapid quantitative immunoassays for gastroenterology applications. The company was created in June 2019 as a spinoff from Prometheus Laboratories and was originally wholly owned by Nestlé Health Science before Biosynex S.A. acquired a 37% stake via a Series A in July 2020 and ultimately acquired the full company in June 2023. Its core technology combines time-resolved Fluorescence Resonance Energy Transfer (trFRET) detection with proprietary Lumiphore chemistry, enabling lab-quality quantitative results from finger-prick whole blood in 2–5 minutes. The product portfolio centers on a compact benchtop instrument and an assay menu spanning C-Reactive Protein (CRP), infliximab (IFX), adalimumab (ADL), and fecal calprotectin (FCP), targeting therapeutic drug monitoring and inflammatory bowel disease management primarily for gastroenterologists and physician office laboratories.

The platform supports multiple specimen types including finger-prick whole blood, venous blood, serum, plasma, urine, saliva, and stool, with a proprietary stool collection device for FCP testing. ProciseDx commercializes through a hybrid model: direct sales to GI specialists and physician offices in the US post-FDA clearance, and a distribution-partner channel in EMEA led by Biosynex across 15+ countries. Revenue is generated through instrument placement (hardware sales) plus recurring assay/reagent kit sales in 20-test kit configurations. The instrument and CRP assay received FDA 510(k) clearance in November 2022; De Novo applications for IFX and ADL were submitted prior to the Biosynex acquisition.

The company operates from a 30,000 sq. ft. ISO 13485–certified facility in San Diego, California. As of mid-2021, more than 100 instruments had been shipped to EMEA, and approximately 30 were installed in the US by November 2022. ProciseDx raised approximately $23.5 million in total disclosed funding ($10.5M Series A in 2020 and a $13M convertible note in 2021) and was acquired by Biosynex S.A. in June 2023 to accelerate US commercialization of infliximab and adalimumab therapeutic drug monitoring tests.

Short descriptiontext

ProciseDx is a San Diego-based point-of-care diagnostics company using trFRET and proprietary Lumiphore technology to deliver 2–5 minute quantitative immunoassay results for gastroenterologists managing inflammatory bowel disease and biologic drug monitoring.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, therapeutic drug monitoring, gastroenterology diagnostics, rapid immunoassay testing, in-vitro diagnostic devices
Industry1 code
PRIMARYHLAHAOAH
Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Point-of-Care Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Instrument Sales
TypeHardware Sales
Description

Sale of ProciseDx diagnostic instruments to physician offices, clinics, and distribution partners

procisedx.com
2Assay/Reagent Kit Sales
TypeOne Time License
Description

Recurring sales of diagnostic assay kits including CRP, IFX, ADL, and FCP tests in 20-test kit configurations

procisedx.com
3Distribution Partnership Revenue
TypeTransaction Fee
Description

Revenue from distribution relationships in EMEA markets through Biosynex and other distributors

procisedx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ProciseDx develops and sells a point-of-care diagnostic platform consisting of a compact trFRET-based instrument and a menu of rapid immunoassay kits. The platform delivers lab-quality quantitative results in 2-5 minutes from a finger-prick blood sample and is targeted primarily at gastroenterology practices for therapeutic drug monitoring of infliximab and adalimumab and inflammatory marker testing (CRP, fecal calprotectin).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Results delivered in 2-5 minutes vs traditional lab testing taking days to weeks
+3 more records
Product overview1 text field

ProciseDx offers a point-of-care diagnostic platform consisting of a compact instrument and a menu of rapid immunoassay tests. The platform uses trFRET (time-resolved fluorescence resonance energy transfer) detection combined with proprietary Lumiphore technology to deliver lab-quality quantitative results in 2-5 minutes. The core product portfolio includes the ProciseDx instrument platform and four main gastroenterology assays: Procise IFX (infliximab therapeutic drug monitoring), Procise ADL (adalimumab therapeutic drug monitoring), Procise CRP (inflammatory marker), and Procise FCP (fecal calprotectin). The system processes multiple sample types including finger prick whole blood, venous blood, serum, plasma, urine, saliva, and stool. The platform has received CE Mark for European commercialization and FDA clearance for the instrument and CRP assay in the United States.

Product and service6 records
1ProciseDx Instrument Platform
CategoryDiagnostic Instrument / Point-of-Care Platform
Description

A compact (approximately shoe-box sized, 8 inches / 20 cm wide) point-of-care diagnostic instrument that uses trFRET detection combined with proprietary Lumiphore technology to deliver lab-quality quantitative immunoassay results in 2-5 minutes. Compatible with finger-prick whole blood, venous blood, serum, plasma, urine, saliva, and stool samples. Sold to physician offices, gastroenterology practices, retail clinics, and urgent care facilities. CE Marked in Europe (Sept 2019) and FDA 510(k) cleared in the United States (Nov 2022).

2Procise IFX (Infliximab) Assay
CategoryDiagnostic Assay Kit (Therapeutic Drug Monitoring)
Description

Therapeutic drug monitoring assay that quantitatively measures infliximab (Remicade and biosimilars Remsima, Inflectra, Flixabi, Renflexis) levels in blood, validated with a reportable range of 1.7-77.2 µg/mL. Delivers results in less than 5 minutes from a finger-prick blood sample on the ProciseDx instrument, enabling same-visit dose adjustments for IBD patients. Intended for gastroenterologists managing IBD patients on infliximab therapy.

3Procise ADL (Adalimumab) Assay
CategoryDiagnostic Assay Kit (Therapeutic Drug Monitoring)
Description

Therapeutic drug monitoring assay that quantitatively measures adalimumab (Humira, Amjevita, Imraldi) levels in blood at the point of care in under 5 minutes from a finger-prick sample. Used by gastroenterologists to adjust biologic dosing for IBD patients during the same patient visit.

4Procise CRP (C-Reactive Protein) Assay
CategoryDiagnostic Assay Kit (Inflammatory Marker)
Description

Quantitative inflammatory marker assay that measures C-Reactive Protein (CRP) levels from finger-prick whole blood, venous blood, or serum in approximately 2 minutes, calibrated against the WHO standard with a reportable range of 3.6 mg/L - 100 mg/L. Performance: 7.0% CV at low QC and 5.4% CV at high QC. Used for monitoring IBD flares and acute inflammation. Sold in 20-test kit configurations.

5Procise FCP (Fecal Calprotectin) Assay
CategoryDiagnostic Assay Kit (Fecal Marker)
Description

Quantitative gastrointestinal assay for measuring fecal calprotectin levels to help differentiate IBS from IBD, predict IBD relapse, and monitor treatment response. Delivers results in 5 minutes from a stool sample collected with the dedicated Procise Stool Collection Device.

6Procise Stool Collection Device
CategorySample Collection Accessory
Description

Specialized sample collection device used with the Procise FCP assay to enable reliable stool sample collection for fecal calprotectin testing at point-of-care.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

ProciseDx serves as US FDA agent and US distributor for Biosynex COVID-19 BSS Antibody test. Initiated clinical trials for finger prick blood claim. Test is a 10-minute blood test detecting anti-SARS CoV-2 antibodies.

2Dr. Magda Marquet
Strategic tierCoreTypeOthers
Description

Board Chair of ProciseDx. Co-founder of Althea Technologies, investor, scientist, entrepreneur and board member of multiple biotech companies. Serves on California governor's advisory committee for COVID crisis.

procisedx.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProciseDx

Point-of-Care Diagnosticsprocisedx.com

ProciseDx is a San Diego-based point-of-care diagnostics company using trFRET and proprietary Lumiphore technology to deliver 2–5 minute quantitative immunoassay results for gastroenterologists managing inflammatory bowel disease and biologic drug monitoring.

What ProciseDx does

ProciseDx is a point-of-care diagnostic platform company specializing in rapid quantitative immunoassays for gastroenterology applications. The company was created in June 2019 as a spinoff from Prometheus Laboratories and was originally wholly owned by Nestlé Health Science before Biosynex S.A. acquired a 37% stake via a Series A in July 2020 and ultimately acquired the full company in June 2023. Its core technology combines time-resolved Fluorescence Resonance Energy Transfer (trFRET) detection with proprietary Lumiphore chemistry, enabling lab-quality quantitative results from finger-prick whole blood in 2–5 minutes. The product portfolio centers on a compact benchtop instrument and an assay menu spanning C-Reactive Protein (CRP), infliximab (IFX), adalimumab (ADL), and fecal calprotectin (FCP), targeting therapeutic drug monitoring and inflammatory bowel disease management primarily for gastroenterologists and physician office laboratories.

The platform supports multiple specimen types including finger-prick whole blood, venous blood, serum, plasma, urine, saliva, and stool, with a proprietary stool collection device for FCP testing. ProciseDx commercializes through a hybrid model: direct sales to GI specialists and physician offices in the US post-FDA clearance, and a distribution-partner channel in EMEA led by Biosynex across 15+ countries. Revenue is generated through instrument placement (hardware sales) plus recurring assay/reagent kit sales in 20-test kit configurations. The instrument and CRP assay received FDA 510(k) clearance in November 2022; De Novo applications for IFX and ADL were submitted prior to the Biosynex acquisition.

The company operates from a 30,000 sq. ft. ISO 13485–certified facility in San Diego, California. As of mid-2021, more than 100 instruments had been shipped to EMEA, and approximately 30 were installed in the US by November 2022. ProciseDx raised approximately $23.5 million in total disclosed funding ($10.5M Series A in 2020 and a $13M convertible note in 2021) and was acquired by Biosynex S.A. in June 2023 to accelerate US commercialization of infliximab and adalimumab therapeutic drug monitoring tests.

ProciseDx firmographics

Firmographics
Name
ProciseDx
Legal name
ProciseDx Corporation
Website
https://procisedx.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
1–10 employees
Short description
ProciseDx is a San Diego-based point-of-care diagnostics company using trFRET and proprietary Lumiphore technology to deliver 2–5 minute quantitative immunoassay results for gastroenterologists managing inflammatory bowel disease and biologic drug monitoring.
Ownership category
akta.pro rank

ProciseDx industry classification

Industry
Product category
Point-of-Care Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAOAH
Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Point-of-care diagnostics
  • Therapeutic drug monitoring
  • Gastroenterology diagnostics
  • Rapid immunoassay testing
  • In-vitro diagnostic devices

Where ProciseDx is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices2 records

Markets served

ProciseDx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Instrument Sales: Sale of ProciseDx diagnostic instruments to physician offices, clinics, and distribution partners
  2. Assay/Reagent Kit Sales: Recurring sales of diagnostic assay kits including CRP, IFX, ADL, and FCP tests in 20-test kit configurations
  3. Distribution Partnership Revenue: Revenue from distribution relationships in EMEA markets through Biosynex and other distributors

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

ProciseDx product offering

Product offering

Core offering

ProciseDx develops and sells a point-of-care diagnostic platform consisting of a compact trFRET-based instrument and a menu of rapid immunoassay kits. The platform delivers lab-quality quantitative results in 2-5 minutes from a finger-prick blood sample and is targeted primarily at gastroenterology practices for therapeutic drug monitoring of infliximab and adalimumab and inflammatory marker testing (CRP, fecal calprotectin).

Product overview

ProciseDx offers a point-of-care diagnostic platform consisting of a compact instrument and a menu of rapid immunoassay tests. The platform uses trFRET (time-resolved fluorescence resonance energy transfer) detection combined with proprietary Lumiphore technology to deliver lab-quality quantitative results in 2-5 minutes. The core product portfolio includes the ProciseDx instrument platform and four main gastroenterology assays: Procise IFX (infliximab therapeutic drug monitoring), Procise ADL (adalimumab therapeutic drug monitoring), Procise CRP (inflammatory marker), and Procise FCP (fecal calprotectin). The system processes multiple sample types including finger prick whole blood, venous blood, serum, plasma, urine, saliva, and stool. The platform has received CE Mark for European commercialization and FDA clearance for the instrument and CRP assay in the United States.

Differentiator

Problem solved

Functional benefit

Products and services

  • ProciseDx Instrument Platform A compact (approximately shoe-box sized, 8 inches / 20 cm wide) point-of-care diagnostic instrument that uses trFRET detection combined with proprietary Lumiphore technology to deliver lab-quality quantitative immunoassay results in 2-5 minutes. Compatible with finger-prick whole blood, venous blood, serum, plasma, urine, saliva, and stool samples. Sold to physician offices, gastroenterology practices, retail clinics, and urgent care facilities. CE Marked in Europe (Sept 2019) and FDA 510(k) cleared in the United States (Nov 2022).
  • Procise IFX (Infliximab) Assay Therapeutic drug monitoring assay that quantitatively measures infliximab (Remicade and biosimilars Remsima, Inflectra, Flixabi, Renflexis) levels in blood, validated with a reportable range of 1.7-77.2 µg/mL. Delivers results in less than 5 minutes from a finger-prick blood sample on the ProciseDx instrument, enabling same-visit dose adjustments for IBD patients. Intended for gastroenterologists managing IBD patients on infliximab therapy.
  • Procise ADL (Adalimumab) Assay Therapeutic drug monitoring assay that quantitatively measures adalimumab (Humira, Amjevita, Imraldi) levels in blood at the point of care in under 5 minutes from a finger-prick sample. Used by gastroenterologists to adjust biologic dosing for IBD patients during the same patient visit.
  • Procise CRP (C-Reactive Protein) Assay Quantitative inflammatory marker assay that measures C-Reactive Protein (CRP) levels from finger-prick whole blood, venous blood, or serum in approximately 2 minutes, calibrated against the WHO standard with a reportable range of 3.6 mg/L - 100 mg/L. Performance: 7.0% CV at low QC and 5.4% CV at high QC. Used for monitoring IBD flares and acute inflammation. Sold in 20-test kit configurations.
  • Procise FCP (Fecal Calprotectin) Assay Quantitative gastrointestinal assay for measuring fecal calprotectin levels to help differentiate IBS from IBD, predict IBD relapse, and monitor treatment response. Delivers results in 5 minutes from a stool sample collected with the dedicated Procise Stool Collection Device.
  • Procise Stool Collection Device Specialized sample collection device used with the Procise FCP assay to enable reliable stool sample collection for fecal calprotectin testing at point-of-care.

Quantifiable outcome

  • Results delivered in 2-5 minutes vs traditional lab testing taking days to weeks
  • +3 more outcomes

Companies that use ProciseDx

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

ProciseDx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ProciseDx partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Biosynex COVID-19 BSS Antibody Test PartnershipminorChannel Partner/ Reseller/ DistributorProciseDx serves as US FDA agent and US distributor for Biosynex COVID-19 BSS Antibody test. Initiated clinical trials for finger prick blood claim. Test is a 10-minute blood test detecting anti-SARS CoV-2 antibodies.
  • Dr. Magda MarquetcoreOthersBoard Chair of ProciseDx. Co-founder of Althea Technologies, investor, scientist, entrepreneur and board member of multiple biotech companies. Serves on California governor's advisory committee for COVID crisis.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

ProciseDx competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

ProciseDx social profiles

Digital presence

ProciseDx compliance and trust

Trust signal

Compliance3 records

ProciseDx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProciseDx leadership team

Management profile

Number of profiles

Profiles7 records

ProciseDx funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProciseDx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProciseDx

What does ProciseDx do?

ProciseDx develops and sells a point-of-care diagnostic platform consisting of a compact trFRET-based instrument and a menu of rapid immunoassay kits. The platform delivers lab-quality quantitative results in 2-5 minutes from a finger-prick blood sample and is targeted primarily at gastroenterology practices for therapeutic drug monitoring of infliximab and adalimumab and inflammatory marker testing (CRP, fecal calprotectin).

Is ProciseDx a public or private company?

ProciseDx is a private company. It is classified as corporate owned and is currently acquired.

When was ProciseDx founded?

ProciseDx was founded in 2019. It employs 1 to 10 people.

Where is ProciseDx based?

ProciseDx is headquartered in Carlsbad, United States, in the North America region.

How does ProciseDx make money?

Three revenue lines are on record. Instrument Sales are the primary driver. The others are assay/Reagent Kit Sales and distribution Partnership Revenue.

Does ProciseDx have an API?

No public API is recorded for ProciseDx.

What industry is ProciseDx in?

ProciseDx's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAHAOAH, Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireProciseDx Expands Intellectual Property Portfolio with Purchase of Two US Therapeutic Drug Monitoring PatentsProciseDx Inc. has purchased two US patents for therapeutic drug monitoring of biologic drugs from W.Health LP to expand its intellectual property portfolio. This acquisition supports ProciseDx's recent FDA clearance for TDM tests and its planned collaboration with Chembio Diagnostics Inc. for assay launches in the US later this year.PR NewswireProciseDx Announces the First FDA-cleared Therapeutic Drug Monitoring Tests for Biologic Drugs, Humira®, Remicade®, and their BiosimilarsProciseDx Inc. received FDA de novo clearance for the first therapeutic drug monitoring (TDM) tests for adalimumab (Humira® and biosimilar Amgevita®) and infliximab (Remicade® and biosimilars Inflectra® and Renflexis®), enabling 5-minute quantitative results compared to the current multi-day process requiring shipment to external laboratories. The tests, intended for use in hospital and moderate complexity clinical laboratories, are expected to launch commercially in Q4 2023 in collaboration with Chembio Diagnostics Inc., targeting the 4.3 million US patients diagnosed with inflammatory bowel disease, of whom up to 15% are treated with these biologic drugs. Biosynex S.A., the French parent company with 100% ownership of ProciseDx, aims to leverage this FDA clearance to reinforce its global leadership position in the TDM market.PR NewswireProciseDx Announces FDA Clearance of ProciseDx instrument and C Reactive Protein (CRP) AssayProciseDx Inc. announced FDA clearance of its ProciseDx instrument and C-reactive Protein (CRP) assay, which delivers quantitative CRP measurements from patient serum in under 5 minutes at point of care. The company has installed 30 instruments in Europe for gastroenterology testing and submitted De Novo applications to the FDA for two therapeutic drug monitoring tests targeting infliximab and adalimumab. ProciseDx also entered a licensing, commercialization, and manufacturing agreement with shareholder Biosynex S.A. to supply and distribute existing ProciseDx products across Europe and the Middle East, with US commercialization of its GI and TDM menu planned for 2023.FinSMEsProciseDx Raises $13M in Convertible Note FinancingSan Diego-based in vitro diagnostics company ProciseDx raised $13 million in convertible note financing from existing shareholders and new investors. The company intends to use the funds to advance FDA submissions for its diagnostic platform and expand its test menu for gastroenterologists.PR NewswireProciseDx Announces $13 Million Convertible Note Financing and Strong International GrowthProciseDx Inc. announced on July 13, 2021 a $13 million convertible note financing to fund international commercialization of its point-of-care diagnostics platform and US regulatory approval, with existing shareholders Nestlé Health Science and Biosynex SA among participants. The company expects 2021 revenues of $2-3 million, has shipped over 100 instruments to EMEA, and has submitted a 510(k) to the FDA.PR NewswireProciseDx Achieves CE Mark for Fecal Calprotectin Point of Care TestingProciseDx Inc. announced it has received CE mark certification for its Fecal Calprotectin (Procise FCP™) point of care test for use on the ProciseDx™ system, enabling diagnosis of Crohn's Disease and Ulcerative Colitis. The test delivers results in under 5 minutes using stool collected by patients at home with a simple device, eliminating the need for special laboratory equipment and facilitating faster clinical decision-making. The test is now available for ProciseDx distributors to sell in CE mark regions (Europe), expanding the company's point-of-care diagnostic menu for gastroenterology facilities.PR NewswireProciseDx Completes Distribution Agreements with D.I.D. in Italy and BHR in the United KingdomProciseDx Inc. has established distribution agreements with BHR Pharmaceuticals Ltd in the United Kingdom and D.I.D. Diagnostic International Distribution S.p.A. in Italy to expand sales of its ProciseDx point-of-care diagnostic platform and related assays for inflammatory bowel disease monitoring. The agreements will bring ProciseDx's rapid diagnostics, which deliver results in as little as 2 minutes from a finger prick blood sample, to healthcare providers in those regions. The company stated it is actively developing relationships in additional EU countries as demand for its therapeutic drug monitoring platform continues to grow.PR NewswireProciseDx Achieves CE Mark for Infliximab and Adalimumab Point of Care TestingProciseDx Inc. announced receipt of CE Mark approval for its infliximab and adalimumab point-of-care tests on the ProciseDx system, enabling European distribution of rapid therapeutic drug monitoring. The tests deliver results in under 5 minutes from fingerpick blood, compared to the previous wait of up to one week that delayed dose adjustments by 2 to 6 weeks. Biosynex S.A., a French diagnostics company, became a shareholder in July 2020 and will distribute the ProciseDx menu in France.Medical Device and Diagnostic industryProciseDx Raises $10.5M in ‘Unconventional’ Series AProciseDx raised $10.5 million in a Series A round led by French diagnostics company Biosynex, which acquired a 37% stake and joined the board. The funding supports the commercialization of point-of-care gastrointestinal tests and establishes a distribution partnership where ProciseDx acts as the US agent for Biosynex's COVID-19 antibody test. Originally spun out from Nestle, the San Diego-based startup aims to launch its GI portfolio in Europe this year while preparing for potential future financing.VC News DailyProciseDx Raises $10.5MProciseDx, a San Diego-based in vitro diagnostics company, raised $10.5 million through equity and debt financing, with $8.5 million in equity and $2 million in debt. The investment round was led by Biosynex, a French diagnostics company, which acquired a 37% stake and board representation, while Nestlé Health Science remains a significant minority shareholder. The funding will support ongoing development and commercialization of ProciseDx's point-of-care diagnostic platform, scale up instrument production, launch products internationally, and fund US clinical trials.